AstraZeneca confirmed Monday morning that it is "exploring potential strategic options" with Acerta Pharma BV.
Acerta is a privately held biopharmaceutical company with offices in California and The Netherlands. Its lead product is an experimental blood cancer drug, called acalabrutinib, which is in late-stage clinical testing.